AVITA Medical Inc (RCEL) Finansal

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California and currently employs 226 full-time employees. The company went IPO on 2012-03-18. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.